| Authors | Random | Allocation | Double-blind | FSD | FSFI | Drop out (%) | Adverse effects |
| Ito et al. 2006 [7] | − | − | + | HSDD | FSFI modified | 0 | No significant difference in adverse effects |
| Chedraui et al. 2006 [8] | − | − | + | + | KI | 11.7 | Not described |
| Akhtari et al. 2014 [9] | + | + | + | HSDD | + | 10.4 | Only one patient reported grade 1 abdominal cramp. |
| Rao et al. 2015 [10] | + | + | + | HSSD | + | 0 | No significant difference in adverse effects |
| Zeinalzadeh et al. 2016 [11] | + | + | + | HSSD | + | 10.7 | Not described |
| Postigo et al. 2016 [13] | − | − | + | FSD | SQ-F, FIEI | 0 | No significant difference in adverse effects |
| De Souza et al. 2016 [12] | + | − | + | HSDD | + | 20 | Not described |
| Vale et al. 2017 [14] | − | − | + | HSDD | + | 37.5 | Not described |
| Bernorio et al. 2018 [15] | + | + | + | FSD | + | 3.3 | Both products were very well tolerated |
| Caruso et al. 2018 [20] | + | − | − | HSDD | + | 26.9 | Not described |
| Caputo et al. 2018 [21] | − | − | − | FSD | + | 3.3 | Not described |
| DRUG-INDUCED FSD (DIFSD) | |||||||
| Meston et al. 2008 [16] | − | − | + | FSD + DIFSD | + | 19.1 | Not described |
| Kashani et al. 2012 [17] | − | − | + | DIFSD | + | 10.5 | Described with no differences |
| Farnia et al. 2015 [18] | + | − | + | DIFSD | + | 0 | No side effects |
| Farnia et al. 2017 [19] | + | − | + | DIFSD | + | 0 | Not described |